Isernia, Italy – A study conducted by the Research Unit of Epidemiology and Prevention at the I.R.C.C.S. Neuromed in Pozzilli, in collaboration with the LUM University of Casamassima, shows that high consumption of ultra-processed foods is associated with the acceleration of biological aging, regardless of the nutritional quality of the...
Latest News
HOUSTON – Iterion Therapeutics, Inc., a venture-backed, clinical stage biotechnology company developing novel cancer therapeutics, announced today that it has confirmed the safety of Tegavivint, a novel, potent and selective nuclear beta-catenin inhibitor, after completing enrollment and dosing the final patient in a multicenter Phase 1/2a dose expansion clinical study...
GARCHING, Germany – ITM AG announced today the successful close of a convertible loan financing totaling EUR 90 million (USD 109 million) led by Petrichor Healthcare Capital Management with participation of additional undisclosed investors. The proceeds will support the expansion of ITM’s precision oncology pipeline as well as fund late-stage development and market access...
INDIANAPOLIS – Researchers from Indiana University-Purdue University Indianapolis (IUPUI) have developed Distributed Drug Discovery (D3), a new low-cost strategy to accelerate the discovery of drugs to treat neglected diseases such as tuberculosis, leprosy, leshmaniasis, dengue fever, and Chagas disease. Even in times of economic prosperity, the pharmaceutical industry has often...
Paris, France – Ivosidenib is under clinical development by Les Laboratoires Servier and currently in Phase II for Chondrosarcoma. According to GlobalData, Phase II drugs for Chondrosarcoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. Ivosidenib overview Ivosidenib (Tibsovo / AG-120) acts as...
IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, announces that it has been awarded a contract by a new US biopharmaceutical client to support its Phase II Huntington’s disease (HD) clinical trial. HD is a rare condition of the nervous system that impacts the way...
Somerset, NJ – Legend Biotech announced in an SEC filing on Tuesday that the FDA will convene its Oncologic Drugs Advisory Committee to discuss the use of its Johnson & Johnson-partnered Carvykti (ciltacabtagene autoleucel) in earlier lines of treatment for multiple myeloma. The panel of external experts will evaluate J&J...
São Paulo, Brazil – In a study with 49 participants, researchers at the State University of Campinas found that daily consumption of a dietary supplement containing 15 g of the substance for five weeks improved glucose metabolism even after meals. The skin or peel of the Jaboticaba berry (Plinia jaboticaba),...
BEIJING, SHANGHAI and BOSTON, Mass. — Jacobio Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced it received approval of registrational phase III clinical trial of the combination therapy between its novel KRAS G12C inhibitor glecirasib and novel SHP2 inhibitor JAB-3312. JAB-3312 is the first SHP2 inhibitor...
BEIJING, China and SAN FRANCISCO, Calif. — Jacobio Pharmaceuticals, a clinical-stage oncology company focusing on undruggable targets, announced data of glecirasib in patients with pancreatic cancer and other solid tumors in the oral abstract session at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (“2024 ASCO GI”). As...